Norman GreenbergVP, Research & Development MedImmune
John MarshallLab Head & Reader in Tumour Biology Barts Cancer Institute
Ralph GraeserAssociate Director Janssen Pharmaceuticals
Robert ShawAssociate Director, Statistics AstraZeneca
Building on the success of the inaugural Tumour Models London, the 2nd Annual meeting will revolutionise your approach to preclinical tumour modelling.
With an even greater focus on the challenges large and small drug developers are currently struggling to overcome, the 2nd Annual Tumour Models London will give you the knowledge and tools you need to develop and utilise the very best preclinical oncology models, and bring successful cancer drugs into the clinic.
Bringing together a perfect cocktail of expert speakers from big and small pharma/biotech, in just 3 days this meeting will help you to:
Make clinically relevant predictions by developing tumour models that are truly representative of patient outcomes, with discussions led by keynote presenter Norman Greenberg
Improve translational success through early identification of clinically relevant biomarkers with Janssen
Minimise late stage attrition and demonstrate a striking correlation between your preclinical data packages and observations in the clinic with Teva Pharmaceuticals and Orion Pharma
Devise effective preclinical strategies to improve the development of immuno-oncology agents by selecting immunologically relevant in vivo models with EMD Serono
Progress candidates down the pipeline by ensuring effective, accurate analysis and interpretation of the data from your models with AstraZeneca
Small and large drug developers who are looking to optimise current tumour models and explore practical alternatives to ensure the effective translation of preclinical data into a clinical setting
Small biotechs looking to showcase their optimised and alternative tumour model platforms
CROs working in preclinical/translational oncology who want to demonstrate how their models and services will deliver on the quality and reproducibility that drug developers need
Academics and researchers looking for opportunities to collaborate and get involved in new consortia